1. United Kingdom In Vitro Diagnostics Market Outlook to 2018 -
Clinical Chemistry Genetic Testing, Haematology, Histology
and Cytology, Immuno Chemistry, Infectious Immunology and
Microbiology Culture
Report Details:
Published:December 2012
No. of Pages: 309
Price: Single User License – US$2500
United Kingdom In Vitro Diagnostics Market Outlook to 2018 - Clinical Chemistry Genetic Testing,
Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and
Microbiology Culture
Summary
GlobalData’s new report, “United Kingdom In Vitro Diagnostics Market Outlook to 2018 - Clinical
Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious
Immunology and Microbiology Culture” provides key market data on the United Kingdom In Vitro
Diagnostics market. The report provides value (USD million), volume (units) and average price
(USD) data for each segment and sub-segment within market categories – Immuno Chemistry,
Clinical Chemistry, Haematology, Infectious Immunology, Histology And Cytology, Microbiology
Culture and Genetic Testing. The report also provides company shares and distribution shares
data for each of the aforementioned market categories. The report is supplemented with global
corporate-level profiles of the key market participants with information on company financials and
pipeline products, wherever available.
This report is built using data and information sourced from proprietary databases, primary and
secondary research and in-house analysis by GlobalData’s team of industry experts.
Scope
- Market size and company share data for In Vitro Diagnostics market categories – Immuno
Chemistry, Clinical Chemistry, Haematology, Infectious Immunology, Histology And Cytology,
Microbiology Culture and Genetic Testing.
- Annualized market revenues (USD million), volume (units) and average price (USD) data for

2. each of the segments and sub-segments within market categories. Data from 2004 to 2011,
forecast forward for 7 years to 2018.
- 2011 company shares and distribution shares data for each of the market categories.
- Global corporate-level profiles of key companies operating within the United Kingdom In Vitro
Diagnostics market.
- Key players covered include Siemens Healthcare, F. Hoffmann-La Roche Ltd., Abbott
Laboratories, Beckman Coulter, Inc., Sysmex Corporation, bioMerieux S.A. and others.
Reasons to buy
- Develop business strategies by identifying the key market categories and segments poised for
strong growth.
- Develop market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the United Kingdom In Vitro
Diagnostics competitive landscape.
- Develop capital investment strategies by identifying the key market segments expected to
register strong growth in the near future.
- What are the key distribution channels and what’s the most preferred mode of product
distribution – Identify, understand and capitalize.
Get your copy of this report @
http://www.reportsnreports.com/reports/213266-united-kingdom-in-vitro-diagnostics-market-outlook-to-2018-
clinical-chemistry-genetic-testing-haematology-histology-and-cytology-immuno-chemistry-infectious-immunology-
and-microbiology-culture.html
Major points covered in Table of Contents of this report include
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 7
1.2 List of Figures 12
2 Introduction 15
2.1 What is This Report About? 15
3 In Vitro Diagnostics In United Kingdom 16
3.1 In Vitro Diagnostics, Market Segmentation 16
3.2 In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Constant, 2004-2018 17
3.3 In Vitro Diagnostics Market, United Kingdom, Revenue Mix ($m), 2011 19
3.4 In Vitro Diagnostics Market, United Kingdom, Category Contribution (%), 2011 20
3.5 In Vitro Diagnostics, United Kingdom, Company Share (2010-2011) 27
4 Clinical Chemistry In United Kingdom 29
4.1 Clinical Chemistry, Market Segmentation 29
4.2 Clinical Chemistry Market, United Kingdom, Revenue Mix ($m), 2011 30
4.3 Clinical Chemistry Market, United Kingdom, Segment Contribution (%), 2011 31
4.4 Clinical Chemistry Overall Revenue, (2004-2018) 32
4.5 Clinical Chemistry Distribution Share (2010-2011) 44

3. 4.6 Clinical Chemistry, United Kingdom, Company Share (2010-2011) 45
5 Genetic Testing In United Kingdom 47
5.1 Genetic Testing, Market Segmentation 47
5.2 Genetic Testing Market, United Kingdom, Revenue Mix ($m), 2011 48
5.3 Genetic Testing Market, United Kingdom, Segment Contribution (%), 2011 49
5.4 Genetic Testing Overall Revenue, (2004-2018) 50
5.5 Genetic Testing Distribution Share (2010-2011) 54
5.6 Genetic Testing, United Kingdom, Company Share (2010-2011) 55
6 Haematology In United Kingdom 57
6.1 Haematology Market, Market Segmentation 57
6.2 Haematology Market, United Kingdom, Revenue Mix ($m), 2011 58
6.3 Haematology Market, United Kingdom, Segment Contribution (%), 2011 59
6.4 Haematology Overall Revenue, (2004-2018) 60
6.5 Haematology Distribution Share (2010-2011) 84
6.6 Haematology, United Kingdom, Company Share (2010-2011) 85
7 Histology And Cytology In United Kingdom 87
7.1 Histology and Cytology Market, Market Segmentation 87
7.2 Histology And Cytology Market, United Kingdom, Revenue Mix ($m), 2011 88
7.3 Histology And Cytology Market, United Kingdom, Segment Contribution (%), 2011 89
7.4 Histology And Cytology Overall Revenue, (2004-2018) 90
7.5 Histology And Cytology Distribution Share (2010-2011) 94
7.6 Histology And Cytology, United Kingdom, Company Share (2010-2011) 95
8 Immuno Chemistry In United Kingdom 97
8.1 Immuno Chemistry Market, United Kingdom, Revenue Mix ($m), 2011 97
8.2 Immuno Chemistry Market, United Kingdom, Segment Contribution (%), 2011 98
8.3 Immuno Chemistry Overall Revenue, (2004-2018) 99
8.4 Immuno Chemistry Distribution Share (2010-2011) 127
8.5 Immuno Chemistry, United Kingdom, Company Share (2010-2011) 128
9 Infectious Immunology In United Kingdom 130
9.1 Infectious Immunology, Market Segmentation 130
9.2 Infectious Immunology Market, United Kingdom, Revenue Mix ($m), 2011 131
9.3 Infectious Immunology Market, United Kingdom, Segment Contribution (%), 2011 132
9.4 Infectious Immunology Overall Revenue, (2004-2018) 133
9.5 Infectious Immunology Distribution Share (2010-2011) 141
9.6 Infectious Immunology, United Kingdom, Company Share (2010-2011) 142
10 Microbiology Culture In United Kingdom 144
10.1 Microbiology Culture, Market Segmentation 144
10.2 Microbiology Culture Market, United Kingdom, Revenue Mix ($m), 2011 145
10.3 Microbiology Culture Market, United Kingdom, Segment Contribution (%), 2011 146
10.4 Microbiology Culture Overall Revenue, (2004-2018) 147
10.5 Microbiology Culture Distribution Share (2010-2011) 155
10.6 Microbiology Culture, United Kingdom, Company Share (2010-2011) 156

4. 11 Overview of Key Companies in United Kingdom In Vitro Diagnostics Market 158
11.1 Siemens Healthcare 158
11.2 F. Hoffmann-La Roche Ltd. 159
11.3 Abbott Laboratories 160
11.4 Beckman Coulter, Inc. 161
11.5 Sysmex Corporation 162
11.6 bioMerieux S.A. 163
11.7 Ortho-Clinical Diagnostics Inc. 164
11.8 Bio-Rad Laboratories, Inc. 164
11.9 Becton, Dickinson and Company 164
11.10 Alere Inc. 165
11.11 Phadia AB 165
11.12 Mindray Medical International Limited 165
11.13 Qiagen N.V. 166
11.14 DiaSorin S.p.A 166
11.15 ELITech Group 167
11.16 PerkinElmer, Inc. 167
11.17 Thermo Fisher Scientific Inc. 168
11.18 Atlas Medical 168
11.19 Gen-Probe Incorporated 168
11.20 Horiba, Ltd. 169
11.21 Diagnostica Stago, Inc. 169
11.22 Life Technologies Corporation 169
11.23 Hologic, Inc. 170
12 In Vitro Diagnostics Market Pipeline Products 171
12.1 Clinical Chemisty Market Pipeline Products 171
12.2 Immuno Chemistry Market Pipeline Products 175
12.3 Haematology Market Pipeline Products 186
12.4 Infectious Immunology Market Pipeline Products 188
12.5 Microbiology Culture Market Pipeline Products 195
12.6 Histology And Cytology Market Pipeline Products 196
12.7 Genetic Testing Market Pipeline Products 197
13 Financial Deals Landscape 202
13.1 Acquisition 202
13.2 Partnerships 208
14 Recent Developments 268
14.1 Strategy And Business Planning 268
14.2 Government and Public Interest 275
14.3 Product News 282
15 Appendix 290
15.1 Definitions of Markets Covered in the Report 291
15.2 Research Methodology 302

5. 15.3 Secondary Research 302
15.4 Primary Research 302
15.5 Models 303
15.6 Forecasts 303
15.7 Expert Panels 303
15.8 GlobalData Consulting 304
15.9 Currency Conversion 304
15.10 Contact Us 304
15.11 Disclaimer 304
1.1 List of Tables
Table 1: In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Constant, 2004-2018
23
Table 2: In Vitro Diagnostics Market, United Kingdom, Category Contribution (%), 2011 25
Table 3: In Vitro Diagnostics Market, United Kingdom, Cross-Category Analysis, 2004-2018 27
Table 4: In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Constant, Historic,
2004-2011 29
Table 5: In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Constant, Forecast,
2011-2018 31
Table 6: In Vitro Diagnostics, United Kingdom, Company Share by Revenue ($m), USD Constant,
2010-2011 33
Table 7: Clinical Chemistry Market, United Kingdom, Segment Contribution (%), 2011 36
Table 8: Clinical Chemistry, United Kingdom, Revenue ($m) USD Constant, by Segment, Historic,
2004-2011 38
Table 9: Clinical Chemistry, United Kingdom, Revenue ($m) USD Constant, by Segment,
Forecast, 2011-2018 40
Table 10: Clinical Chemisty Analyzers, United Kingdom, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 42
Table 11: Clinical Chemisty Analyzers, United Kingdom, Revenue ($m) USD Constant, by Sub-
Segment, Forecast, 2011-2018 44
Table 12: Urine Analysis, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment,
Historic, 2004-2011 46
Table 13: Urine Analysis, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment,
Forecast, 2011-2018 48
Table 14: Clinical Chemistry, United Kingdom, Distribution Share by Revenue ($m), USD
Constant, 2010-2011 49
Table 15: Clinical Chemistry, United Kingdom, Company Share by Revenue ($m), USD Constant,
2010-2011 51
Table 16: Genetic Testing Market, United Kingdom, Segment Contribution (%), 2011 54
Table 17: Genetic Testing, United Kingdom, Revenue ($m) USD Constant, by Segment, Historic,
2004-2011 56
Table 18: Genetic Testing, United Kingdom, Revenue ($m) USD Constant, by Segment, Forecast,

6. 2011-2018 58
Table 19: Genetic Testing, United Kingdom, Distribution Share by Revenue ($m), USD Constant,
2010-2011 59
Table 20: Genetic Testing, United Kingdom, Company Share by Revenue ($m), USD Constant,
2010-2011 61
Table 21: Haematology Market, United Kingdom, Segment Contribution (%), 2011 64
Table 22: Haematology, United Kingdom, Revenue ($m) USD Constant, by Segment, Historic,
2004-2011 66
Table 23: Haematology, United Kingdom, Revenue ($m) USD Constant, by Segment, Forecast,
2011-2018 68
Table 24: Haematology Reagents, United Kingdom, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 70
Table 25: Haematology Reagents, United Kingdom, Revenue ($m) USD Constant, by Sub-
Segment, Forecast, 2011-2018 72
Table 26: Immunohaematology, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment,
Historic, 2004-2011 74
Table 27: Immunohaematology, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment,
Forecast, 2011-2018 76
Table 28: Haemostasis, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment,
Historic, 2004-2011 78
Table 29: Haemostasis, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment,
Forecast, 2011-2018 80
Table 30: Haematology Rapid Tests, United Kingdom, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 82
Table 31: Haematology Rapid Tests, United Kingdom, Revenue ($m) USD Constant, by Sub-
Segment, Forecast, 2011-2018 84
Table 32: Haematology Cell Counters, United Kingdom, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 86
Table 33: Haematology Cell Counters, United Kingdom, Revenue ($m) USD Constant, by Sub-
Segment, Forecast, 2011-2018 88
Table 34: Haematology, United Kingdom, Distribution Share by Revenue ($m), USD Constant,
2010-2011 89
Table 35: Haematology, United Kingdom, Company Share by Revenue ($m), USD Constant,
2010-2011 91
Table 36: Histology And Cytology Market, United Kingdom, Segment Contribution (%), 2011 94
Table 37: Histology And Cytology, United Kingdom, Revenue ($m) USD Constant, by Segment,
Historic, 2004-2011 96
Table 38: Histology And Cytology, United Kingdom, Revenue ($m) USD Constant, by Segment,
Forecast, 2011-2018 98
Table 39: Histology And Cytology, United Kingdom, Distribution Share by Revenue ($m), USD
Constant, 2010-2011 99
Table 40: Histology And Cytology, United Kingdom, Company Share by Revenue ($m), USD

7. Constant, 2010-2011 101
Table 41: Immuno Chemistry Market, United Kingdom, Segment Contribution (%), 2011 103
Table 42: Immuno Chemistry, United Kingdom, Revenue ($m) USD Constant, by Segment,
Historic, 2004-2011 105
Table 43: Immuno Chemistry, United Kingdom, Revenue ($m) USD Constant, by Segment,
Forecast, 2011-2018 107
Table 44: Disease Specific Immunochemistry, United Kingdom, Revenue ($m) USD Constant, by
Sub-Segment, Historic, 2004-2011 109
Table 45: Disease Specific Immunochemistry, United Kingdom, Revenue ($m) USD Constant, by
Sub-Segment, Forecast, 2011-2018 111
Table 46: Drugs of Abuse / Toxicology, United Kingdom, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 113
Table 47: Drugs of Abuse / Toxicology, United Kingdom, Revenue ($m) USD Constant, by Sub-
Segment, Forecast, 2011-2018 115
Table 48: Endocrinology Tests, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment,
Historic, 2004-2011 117
Table 49: Endocrinology Tests, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment,
Forecast, 2011-2018 119
Table 50: Immunochemistry Rapid Tests, United Kingdom, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 121
Table 51: Immunochemistry Rapid Tests, United Kingdom, Revenue ($m) USD Constant, by Sub-
Segment, Forecast, 2011-2018 123
Table 52: Therapeutic Drug Monitoring, United Kingdom, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 125
Table 53: Therapeutic Drug Monitoring, United Kingdom, Revenue ($m) USD Constant, by Sub-
Segment, Forecast, 2011-2018 127
Table 54: Immunochemistry Analyzers, United Kingdom, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 129
Table 55: Immunochemistry Analyzers, United Kingdom, Revenue ($m) USD Constant, by Sub-
Segment, Forecast, 2011-2018 131
Table 56: Immuno Chemistry, United Kingdom, Distribution Share by Revenue ($m), USD
Constant, 2010-2011 132
Table 57: Immuno Chemistry, United Kingdom, Company Share by Revenue ($m), USD Constant,
2010-2011 134
Table 58: Infectious Immunology Market, United Kingdom, Segment Contribution (%), 2011 137
Table 59: Infectious Immunology, United Kingdom, Revenue ($m) USD Constant, by Segment,
Historic, 2004-2011 139
Table 60: Infectious Immunology, United Kingdom, Revenue ($m) USD Constant, by Segment,
Forecast, 2011-2018 141
Table 61: Infectious Immunology Rapid Tests, United Kingdom, Revenue ($m) USD Constant, by
Sub-Segment, Historic, 2004-2011 143
Table 62: Infectious Immunology Rapid Tests, United Kingdom, Revenue ($m) USD Constant, by

8. Sub-Segment, Forecast, 2011-2018 145
Table 63: Infectious Immunology, United Kingdom, Distribution Share by Revenue ($m), USD
Constant, 2010-2011 146
Table 64: Infectious Immunology, United Kingdom, Company Share by Revenue ($m), USD
Constant, 2010-2011 148
Table 65: Microbiology Culture Market, United Kingdom, Segment Contribution (%), 2011 151
Table 66: Microbiology Culture, United Kingdom, Revenue ($m) USD Constant, by Segment,
Historic, 2004-2011 153
Table 67: Microbiology Culture, United Kingdom, Revenue ($m) USD Constant, by Segment,
Forecast, 2011-2018 155
Table 68: Microbiology Analyzers, United Kingdom, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 157
Table 69: Microbiology Analyzers, United Kingdom, Revenue ($m) USD Constant, by Sub-
Segment, Forecast, 2011-2018 159
Table 70: Microbiology Culture, United Kingdom, Distribution Share by Revenue ($m), USD
Constant, 2010-2011 160
Table 71: Microbiology Culture, United Kingdom, Company Share by Revenue ($m), USD
Constant, 2010-2011 162
Table 72: Clinical Chemisty Market Pipeline Products 176
Table 73: Immuno Chemistry Market Pipeline Products 180
Table 74: Haematology Market Pipeline Products 191
Table 75: Infectious Immunology Market Pipeline Products 193
Table 76: Microbiology Culture Market Pipeline Products 200
Table 77: Histology And Cytology Market Pipeline Products 201
Table 78: Genetic Testing Market Pipeline Products 202
Table 79: Illumina Acquires BlueGnome, Provider Of Cytogenetics And In Vitro Fertilization
Screening Solutions 207
Table 80: Becton, Dickinson Acquires Sirigen, Developer Of Polymer Dyes 208
Table 81: Abingdon Health Acquires 80% Stake In Forsite Diagnostics 210
Table 82: Abingdon Health To Acquire 50.1% Stake In Molecular Vision From Imperial Innovations
Group 211
Table 83: Quintiles Acquires Minority Stake In Oxford Cancer Biomarkers For $5 Million 212
Table 84: bioMerieux Enters Into Licensing Agreement With Quanterix For Simoa Technology 213
Table 85: Crown Bioscience Enters Into Co-Development Agreement With Horizon Discovery 214
Table 86: Affinity Biosensors Enters Into Distribution Agreement With Malvern Instruments For
Archimedes Particle Metrology System 215
Table 87: Agenix Enters Into Licensing Agreement With Tyrian Diagnostics For DiagnostIQ 216
Table 88: BioDot Enters Into Co-Marketing Agreement With JOT Automation 217
Table 89: AbD Serotec Enters Into Licensing Agreement With DiaSorin For HuCAL Antibodies 218
Table 90: BD Diagnostic Systems Enters Into Agreement With Lab21 To Develop New Oncology
Assays 219
Table 91: CellaVision Enters Into Distribution Agreement With Siemens Healthcare For Digital

9. Microscopy Hematology Solutions 220
Table 92: Med BioGene Amends Licensing Agreement With Precision Therapeutics For
LungExpress Dx Test 221
Table 93: Ovizio Imaging Systems Enters Into Distribution Agreement With Applikon
Biotechnology 222
Table 94: Life Technologies Enters Into Co-Marketing Agreement With Pathogenica 223
Table 95: CML HealthCare Enters Into Agreement With MaRS Innovation 224
Table 96: Akrivis Technologies Enters Into Co-Development Agreement With United States
Biological 225
Table 97: Castle Biosciences Enters Into Licensing Agreement With Brigham and Women''s
Hospital For Mesothelioma Test 226
Table 98: Scienion Enters Into Co-Marketing Agreement With Maine Manufacturing For Protein
Array Products 227
Table 99: GeneCentric Diagnostics Enters Into Licensing Agreement With University of North
Carolina 228
Table 100: Dolomite Centre Enters Into Licensing Agreement With Japan Science and Technology
Agency For Microdroplet Generation Technology 229
Table 101: Epistem Enters Into Distribution Agreement With Becton Dickinson For Mycobacterium
TB Test 230
Table 102: Waters Enters Into Co-Development Agreement With Nonlinear Dynamics 231
Table 103: EKF Diagnostics Enters Into Licensing Agreement With Joslin Diabetes Center 232
Table 104: SciFluor Life Sciences Enters Into Distribution Agreement With Sigma-Aldrich For
PhenoFluor 233
Table 105: Immuno-Biological Labs Enters Into Licensing Agreement With IBL International 234
Table 106: MDxHealth Enters Into Licensing Agreement With Merck For MGMT Diagnostic Test
235
Table 107: Lab21 Enters Into Co-Development Agreement With Pharma Company 236
Table 108: NicOx Enters Into Licensing Agreement With Rapid Pathogen Screening For
AdenoPlus 237
Table 109: Immunexpress Enters Into Licensing Agreement With Debiopharm And Biocartis 238
Table 110: Omega Diagnostics Enters Into Licensing Agreement With Burnet Institute For CD4
POC Test 239
Table 111: KineMed Enters Into Co-Development Agreement With GlaxoSmithKline 240
Table 112: One Lambda Enters Into Co-Marketing Agreement With CellTrend 241
Table 113: GE Healthcare Enters Into Co-Development Agreement With Commonwealth Scientific
and Industrial Research 242
Table 114: Clarient Diagnostic Services Enters Into Licensing Agreement With Insight Genetics
For ALK Cancer Biomarker 243
Table 115: Affymetrix Enters Into Technology Integration Agreement With Leica Microsystems 244
Table 116: Biocartis Enters Into Co-Development Agreement With Wellcome Trust Sanger
Institute And Philips Research Europe For Oncology Diagnostics 245
Table 117: Ventana Medical Enters Into Licensing Agreement With Gen-Probe For IP Of ERG

10. Marker 246
Table 118: Affymetrix Enters Into Distribution Agreement With ScreenCell For Circulating Tumor
Cell Technology 247
Table 119: Hycor Biomedical Enters Into Distribution Agreement With Roche For KOVA 248
Table 120: Opko Health Enters Into Licensing Agreement With International Health Technology
For Prostate Cancer Biomarker Panel 249
Table 121: Dolomite Centre Enters Into Co-Development Agreement With LioniX 250
Table 122: Genome Diagnostics Enters Into Co-Marketing Agreement With Qiagen For
LongRange PCR Kit 251
Table 123: Biofortuna Extends Co-Marketing Agreement With Abbott Labs For SSPGo 252
Table 124: Novo Nordisk Enters Into Co-Development Agreement With Oxford University 253
Table 125: Pressure BioSciences Enters Into Licensing Agreement With Target Discovery For
Pressure Cycling Technology 254
Table 126: LipoScience Enters Into Licensing Agreement With Cleveland Clinic 255
Table 127: GE Healthcare Enters Into Co-Development Agreement With NXT2B For Compact
Cyclotron And PET Tracer System 256
Table 128: NexDx Enters Into Licensing Agreement With University of California For Epigenetic
Biomarkers 257
Table 129: LAB21 Enters Into Co-Development Agreement With IVD Company For Aspergillus
Molecular Assay 258
Table 130: Randox Labs Enters Into Licensing Agreement With Proteome Sciences For Stroke
Biomarker 259
Table 131: Bio-Rad Labs Extends Distribution Agreement With Luminex For MAGPIX 260
Table 132: A*STAR Enters Into Co-Development Agreement With QuantuMDx Group 261
Table 133: DiaGenic Enters Into Co-Development Agreement With GE Healthcare 262
Table 134: DNA Electronics Enters Into Licensing Agreement With Gene Onyx For Genalysis
Technology 263
Table 135: Epistem Holdings Enters Into Co-Development Agreement With GlaxoSmithKline 264
Table 136: ANGLE Enters Into Co-Development Agreement With Paterson Institute for Cancer
Research 265
Table 137: Yissum Research Development Company Enters Into Licensing Agreement With
BioConnections For Commercialization Of Kits 266
Table 138: Oxford Gene Technology Enters Into Licensing Agreement With Oslo University
Hospital And University of Oslo 267
Table 139: VolitionRx And Abcodia Partner To Advance Discovery Of Blood Based Biomarkers
For Cancer 268
Table 140: Horizon Diagnostics Enters Into Licensing Agreement With UK NEQAS 269
Table 141: Thermo Fisher Scientific Enters Into Distribution Agreement With Abbott For PCT
Assay For Sepsis 270
Table 142: Abbott Labs Expands Its Co-Development Agreement With GlaxoSmithKline
Biologicals 271
Table 143: Dolomite Enters Into Co-Development Agreement With Clearbridge BioMedics 272

11. 1.2 List of Figures
Figure 1: In Vitro Diagnostics, Market Segmentation 21
Figure 2: In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Constant, 2004-2018
22
Figure 3: In Vitro Diagnostics Market, United Kingdom, Revenue Mix ($m), 2011 24
Figure 4: In Vitro Diagnostics Market, United Kingdom, Category Contribution (%), 2011 25
Figure 5: In Vitro Diagnostics Market, United Kingdom, Cross-Category Analysis, 2004-2018 26
Figure 6: In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Constant, Historic,
2004-2011 28
Figure 7: In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Constant, Forecast,
2011-2018 30
Figure 8: In Vitro Diagnostics, United Kingdom, Company Share (%), 2011 32
Figure 9: Clinical Chemistry, Market Segmentation 34
Figure 10: Clinical Chemistry Market, United Kingdom, Revenue Mix ($m), 2011 35
Figure 11: Clinical Chemistry Market, United Kingdom, Segment Contribution (%), 2011 36
Figure 12: Clinical Chemistry, United Kingdom, Revenue ($m) USD Constant, by Segment,
Historic, 2004-2011 37
Figure 13: Clinical Chemistry, United Kingdom, Revenue ($m) USD Constant, by Segment,
Forecast, 2011-2018 39
Figure 14: Clinical Chemisty Analyzers, United Kingdom, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 41
Figure 15: Clinical Chemisty Analyzers, United Kingdom, Revenue ($m) USD Constant, by Sub-
Segment, Forecast, 2011-2018 43
Figure 16: Urine Analysis, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment,
Historic, 2004-2011 45
Figure 17: Urine Analysis, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment,
Forecast, 2011-2018 47
Figure 18: Clinical Chemistry, United Kingdom, Company Share (%), 2011 50
Figure 19: Genetic Testing, Market Segmentation 52
Figure 20: Genetic Testing Market, United Kingdom, Revenue Mix ($m), 2011 53
Figure 21: Genetic Testing Market, United Kingdom, Segment Contribution (%), 2011 54
Figure 22: Genetic Testing, United Kingdom, Revenue ($m) USD Constant, by Segment, Historic,
2004-2011 55
Figure 23: Genetic Testing, United Kingdom, Revenue ($m) USD Constant, by Segment,
Forecast, 2011-2018 57
Figure 24: Genetic Testing, United Kingdom, Company Share (%), 2011 60
Figure 25: Haematology Market, Market Segmentation 62
Figure 26: Haematology Market, United Kingdom, Revenue Mix ($m), 2011 63
Figure 27: Haematology Market, United Kingdom, Segment Contribution (%), 2011 64
Figure 28: Haematology, United Kingdom, Revenue ($m) USD Constant, by Segment, Historic,
2004-2011 65

12. Figure 29: Haematology, United Kingdom, Revenue ($m) USD Constant, by Segment, Forecast,
2011-2018 67
Figure 30: Haematology Reagents, United Kingdom, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 69
Figure 31: Haematology Reagents, United Kingdom, Revenue ($m) USD Constant, by Sub-
Segment, Forecast, 2011-2018 71
Figure 32: Immunohaematology, United Kingdom, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 73
Figure 33: Immunohaematology, United Kingdom, Revenue ($m) USD Constant, by Sub-
Segment, Forecast, 2011-2018 75
Figure 34: Haemostasis, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment,
Historic, 2004-2011 77
Figure 35: Haemostasis, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment,
Forecast, 2011-2018 79
Figure 36: Haematology Rapid Tests, United Kingdom, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 81
Figure 37: Haematology Rapid Tests, United Kingdom, Revenue ($m) USD Constant, by Sub-
Segment, Forecast, 2011-2018 83
Figure 38: Haematology Cell Counters, United Kingdom, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 85
Figure 39: Haematology Cell Counters, United Kingdom, Revenue ($m) USD Constant, by Sub-
Segment, Forecast, 2011-2018 87
Figure 40: Haematology, United Kingdom, Company Share (%), 2011 90
Figure 41: Histology and Cytology Market, Market Segmentation 92
Figure 42: Histology And Cytology Market, United Kingdom, Revenue Mix ($m), 2011 93
Figure 43: Histology And Cytology Market, United Kingdom, Segment Contribution (%), 2011 94
Figure 44: Histology And Cytology, United Kingdom, Revenue ($m) USD Constant, by Segment,
Historic, 2004-2011 95
Figure 45: Histology And Cytology, United Kingdom, Revenue ($m) USD Constant, by Segment,
Forecast, 2011-2018 97
Figure 46: Histology And Cytology, United Kingdom, Company Share (%), 2011 100
Figure 47: Immuno Chemistry Market, United Kingdom, Revenue Mix ($m), 2011 102
Figure 48: Immuno Chemistry Market, United Kingdom, Segment Contribution (%), 2011 103
Figure 49: Immuno Chemistry, United Kingdom, Revenue ($m) USD Constant, by Segment,
Historic, 2004-2011 104
Figure 50: Immuno Chemistry, United Kingdom, Revenue ($m) USD Constant, by Segment,
Forecast, 2011-2018 106
Figure 51: Disease Specific Immunochemistry, United Kingdom, Revenue ($m) USD Constant, by
Sub-Segment, Historic, 2004-2011 108
Figure 52: Disease Specific Immunochemistry, United Kingdom, Revenue ($m) USD Constant, by
Sub-Segment, Forecast, 2011-2018 110
Figure 53: Drugs of Abuse / Toxicology, United Kingdom, Revenue ($m) USD Constant, by Sub-

13. Segment, Historic, 2004-2011 112
Figure 54: Drugs of Abuse / Toxicology, United Kingdom, Revenue ($m) USD Constant, by Sub-
Segment, Forecast, 2011-2018 114
Figure 55: Endocrinology Tests, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment,
Historic, 2004-2011 116
Figure 56: Endocrinology Tests, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment,
Forecast, 2011-2018 118
Figure 57: Immunochemistry Rapid Tests, United Kingdom, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 120
Figure 58: Immunochemistry Rapid Tests, United Kingdom, Revenue ($m) USD Constant, by Sub-
Segment, Forecast, 2011-2018 122
Figure 59: Therapeutic Drug Monitoring, United Kingdom, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 124
Figure 60: Therapeutic Drug Monitoring, United Kingdom, Revenue ($m) USD Constant, by Sub-
Segment, Forecast, 2011-2018 126
Figure 61: Immunochemistry Analyzers, United Kingdom, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 128
Figure 62: Immunochemistry Analyzers, United Kingdom, Revenue ($m) USD Constant, by Sub-
Segment, Forecast, 2011-2018 130
Figure 63: Immuno Chemistry, United Kingdom, Company Share (%), 2011 133
Figure 64: Infectious Immunology, Market Segmentation 135
Figure 65: Infectious Immunology Market, United Kingdom, Revenue Mix ($m), 2011 136
Figure 66: Infectious Immunology Market, United Kingdom, Segment Contribution (%), 2011 137
Figure 67: Infectious Immunology, United Kingdom, Revenue ($m) USD Constant, by Segment,
Historic, 2004-2011 138
Figure 68: Infectious Immunology, United Kingdom, Revenue ($m) USD Constant, by Segment,
Forecast, 2011-2018 140
Figure 69: Infectious Immunology Rapid Tests, United Kingdom, Revenue ($m) USD Constant, by
Sub-Segment, Historic, 2004-2011 142
Figure 70: Infectious Immunology Rapid Tests, United Kingdom, Revenue ($m) USD Constant, by
Sub-Segment, Forecast, 2011-2018 144
Figure 71: Infectious Immunology, United Kingdom, Company Share (%), 2011 147
Figure 72: Microbiology Culture, Market Segmentation 149
Figure 73: Microbiology Culture Market, United Kingdom, Revenue Mix ($m), 2011 150
Figure 74: Microbiology Culture Market, United Kingdom, Segment Contribution (%), 2011 151
Figure 75: Microbiology Culture, United Kingdom, Revenue ($m) USD Constant, by Segment,
Historic, 2004-2011 152
Figure 76: Microbiology Culture, United Kingdom, Revenue ($m) USD Constant, by Segment,
Forecast, 2011-2018 154
Figure 77: Microbiology Analyzers, United Kingdom, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 156
Figure 78: Microbiology Analyzers, United Kingdom, Revenue ($m) USD Constant, by Sub-

14. Segment, Forecast, 2011-2018 158
Figure 79: Microbiology Culture, United Kingdom, Company Share (%), 2011 161
Figure 80: Siemens Healthcare, Company Share (%),United Kingdom In Vitro Diagnostics Market,
2011 163
Figure 81: F. Hoffmann-La Roche Ltd., Company Share (%),United Kingdom In Vitro Diagnostics
Market, 2011 164
Figure 82: Abbott Laboratories, Company Share (%),United Kingdom In Vitro Diagnostics Market,
2011 165
Figure 83: Beckman Coulter, Inc., Company Share (%),United Kingdom In Vitro Diagnostics
Market, 2011 166
Figure 84: Sysmex Corporation, Company Share (%),United Kingdom In Vitro Diagnostics Market,
2011 167
Figure 85: bioMerieux S.A., Company Share (%),United Kingdom In Vitro Diagnostics Market,
2011 168
Contact: sales@reportsandreports.com for more information.